JP2019534251A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534251A5 JP2019534251A5 JP2019516622A JP2019516622A JP2019534251A5 JP 2019534251 A5 JP2019534251 A5 JP 2019534251A5 JP 2019516622 A JP2019516622 A JP 2019516622A JP 2019516622 A JP2019516622 A JP 2019516622A JP 2019534251 A5 JP2019534251 A5 JP 2019534251A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- taxane
- body surface
- surface area
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662401638P | 2016-09-29 | 2016-09-29 | |
| US62/401,638 | 2016-09-29 | ||
| PCT/US2017/053954 WO2018064299A1 (en) | 2016-09-29 | 2017-09-28 | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019534251A JP2019534251A (ja) | 2019-11-28 |
| JP2019534251A5 true JP2019534251A5 (enExample) | 2020-11-12 |
Family
ID=60186360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516622A Pending JP2019534251A (ja) | 2016-09-29 | 2017-09-28 | Ｍｅｋ阻害剤、ｐｄ−１軸阻害剤、及びタキサンを用いた併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190209701A1 (enExample) |
| EP (1) | EP3518970A1 (enExample) |
| JP (1) | JP2019534251A (enExample) |
| KR (1) | KR20190061030A (enExample) |
| CN (1) | CN109862917A (enExample) |
| AU (1) | AU2017335839A1 (enExample) |
| BR (1) | BR112019005815A2 (enExample) |
| CA (1) | CA3038671A1 (enExample) |
| IL (1) | IL265668A (enExample) |
| MX (1) | MX2019003603A (enExample) |
| TW (1) | TW201815419A (enExample) |
| WO (1) | WO2018064299A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL256080B2 (en) | 2015-06-17 | 2025-06-01 | Genentech Inc | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
| MX2021003213A (es) * | 2018-09-21 | 2021-05-12 | Genentech Inc | Metodos de diagnostico para cancer de mama triple negativo. |
| WO2020079581A1 (en) * | 2018-10-16 | 2020-04-23 | Novartis Ag | Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy |
| EP3897612A1 (en) * | 2018-12-19 | 2021-10-27 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising an akt inhibitor, a taxane, and a pd-l1 inhibitor |
| CA3181820A1 (en) * | 2020-06-16 | 2021-12-23 | Genentech, Inc. | Methods and compositions for treating triple-negative breast cancer |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ES2087997T3 (es) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | Generacion de anticuerpos xenogenicos. |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| AU760562B2 (en) | 1997-12-05 | 2003-05-15 | Scripps Research Institute, The | Humanization of murine antibody |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| US8146000B1 (en) | 2005-10-07 | 2012-03-27 | Goodwell Technologies, Inc. | Integrated transactional workflows distributed across multiple contact centers |
| DE602006021205D1 (de) | 2005-10-07 | 2011-05-19 | Exelixis Inc | Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen |
| EP2242773B1 (en) | 2008-02-11 | 2017-06-14 | Cure Tech Ltd. | Monoclonal antibodies for tumor treatment |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| EP2328920A2 (en) | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Targeted costimulatory polypeptides and methods of use to treat cancer |
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| EA026924B1 (ru) * | 2011-08-01 | 2017-05-31 | Дженентек, Инк. | Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek |
| SI2884979T1 (sl) | 2012-08-17 | 2019-10-30 | Hoffmann La Roche | Kombinirana zdravljenja melanoma, ki vključujejo dajanje kobimetiniba in vemurafeniba |
| JP6300042B2 (ja) | 2012-10-12 | 2018-03-28 | エグゼリクシス， インコーポレイテッド | 癌の処置に使用するための化合物の製造方法 |
| CA2934028A1 (en) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| NZ760065A (en) * | 2013-12-17 | 2022-12-23 | Genentech Inc | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| IL256080B2 (en) * | 2015-06-17 | 2025-06-01 | Genentech Inc | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
-
2017
- 2017-09-28 CN CN201780065799.4A patent/CN109862917A/zh active Pending
- 2017-09-28 TW TW106133384A patent/TW201815419A/zh unknown
- 2017-09-28 BR BR112019005815A patent/BR112019005815A2/pt not_active Application Discontinuation
- 2017-09-28 CA CA3038671A patent/CA3038671A1/en not_active Abandoned
- 2017-09-28 JP JP2019516622A patent/JP2019534251A/ja active Pending
- 2017-09-28 WO PCT/US2017/053954 patent/WO2018064299A1/en not_active Ceased
- 2017-09-28 EP EP17791212.8A patent/EP3518970A1/en not_active Withdrawn
- 2017-09-28 KR KR1020197011867A patent/KR20190061030A/ko not_active Ceased
- 2017-09-28 MX MX2019003603A patent/MX2019003603A/es unknown
- 2017-09-28 AU AU2017335839A patent/AU2017335839A1/en not_active Abandoned
-
2019
- 2019-03-27 US US16/366,411 patent/US20190209701A1/en not_active Abandoned
- 2019-03-27 IL IL265668A patent/IL265668A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534251A5 (enExample) | ||
| JP2018108086A5 (enExample) | ||
| JP2018184417A5 (enExample) | ||
| JP2019524820A5 (enExample) | ||
| JP2017503820A5 (enExample) | ||
| JP2020002171A5 (enExample) | ||
| JP2012525853A5 (enExample) | ||
| JP2015527318A5 (enExample) | ||
| JP2018506550A5 (enExample) | ||
| JP2017501167A5 (enExample) | ||
| IL300151A (en) | Combinations for the treatment of cancer | |
| JP2015529225A5 (enExample) | ||
| JP2014515373A5 (enExample) | ||
| JP2020521797A5 (enExample) | ||
| JP2019517549A5 (enExample) | ||
| JP2015530867A5 (enExample) | ||
| JP2016503413A5 (enExample) | ||
| JP2017160178A5 (enExample) | ||
| RU2015151454A (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ НА ОСНОВЕ АФУКОЗИЛИРОВАННОГО АНТИТЕЛА К CD20 В СОЧЕТАНИИ С КОНЪЮГАТОМ АНТИТЕЛО К CD79b-ЛЕКАРСТВЕННОЕ СРЕДСТВО | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2018522851A5 (enExample) | ||
| JP2018530578A5 (enExample) | ||
| JP2013515485A5 (enExample) | ||
| JPWO2020111018A5 (enExample) | ||
| JP2018526460A5 (enExample) |